Global pharmaceutical giants are increasing investments in China's biotech sector, aiming to leverage innovation capabilities and form joint ventures for the global market, according to Global Health Summit speakers.
Leading Chinese brokerages expressed optimism for domestic tech shares in August, distinguishing them from sharp sell-offs in South Korean financial markets.
AgiBot had eyed a Hong Kong listing this year, targeting a HK$40-50 billion valuation, with CICC and Morgan Stanley as potential joint sponsors. Separately, Innolight's IPO, aiming to raise US$8 billion, attracted over 30 cornerstone investors for a July 30 debut, potentially the city's biggest listing in seven years.
Shenzhen-based Luxshare, a key Apple supplier, has secured regulatory approval for a Hong Kong listing after receiving the green light from the China Securities Regulatory Commission. The company reported a 24% revenue surge to 332 billion yuan and a 24% net profit increase to 16.6 billion yuan in 2025.
Chinese biotech companies are pursuing global commercialization despite US regulatory barriers, leveraging cost advantages in markets like Europe. Insilico Medicine's Ren Feng highlighted the need for internationalization and the challenge of lacking overseas clinical teams, suggesting business development deals as a solution.
MiniMax, a Shanghai-based AI company, hires Citic Securities to prepare for a yuan-denominated share sale on China's onshore market, capitalizing on heightened global investor interest in AI stocks.
The parent company of Yangtze Memory Technologies Co, China's leading 3D NAND flash memory manufacturer, has officially begun the tutoring process for an initial public offering, according to a regulatory filing.
YMTC, China's leading 3D NAND flash memory manufacturer, is preparing for an IPO. Its parent company has begun the official tutoring process with Citic Securities and China Securities, signaling a push for capital market involvement in the nation's semiconductor self-reliance efforts.
With global attention fixed on the US and Iranian shipping blockades in the Strait of Hormuz and how many vessels have traversed the critically important waterway, a leading Chinese investment bank has been calculating the long-term gains and losses and how they could rewrite the global economic order. The United States was on the horns of a dilemma over the strait that might herald an acceleration of Washington’s strategic retreat and its increasingly transactional relationships with other...
